Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that showed both the COVID-19-Influenza Combination and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid and Fluzone HD, respectively.
"Both our combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated. This data set adds to findings from our Phase 2 trial and will help inform discussions with potential partners," said Ruxandra Draghia-Akli, Executive Vice President and Head of Research and Development, Novavax.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.